Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre V Ivachtchenko

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Journal of Medicinal Chemistry|August 14, 2020
Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza VirusesAndrei A Ivashchenko, Oleg D Mitkin, Jeremy C Jones, et al.
Emerging Infectious Diseases|March 10, 2025
Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023-2024Philippe Noriel Q Pascua, Anton Chesnokov, Ha T Nguyen, et al.
Antiviral Research|July 26, 2023
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022Ha T Nguyen, Anton Chesnokov, Juan De La Cruz, et al.
Journal of Medicinal Chemistry|August 23, 2014
Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025)Alexandre V Ivachtchenko, Oleg D Mitkin, Pavel M Yamanushkin, et al.
Viruses|July 2, 2021
Effect of Aprotinin and Avifavir<sup>®</sup> Combination Therapy for Moderate COVID-19 PatientsAndrey A Ivashchenko, Valeria N Azarova, Alina N Egorova, et al.
The Journal of Antimicrobial Chemotherapy|December 28, 2020
Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavirAndrei A Ivashchenko, Oleg D Mitkin, Jeremy C Jones, et al.
Journal of Psychiatric Research|October 17, 2021
Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot studyAndrey A Ivashchenko, Margarita A Morozova, Natalia V Vostokova, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 10, 2020
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical TrialAndrey A Ivashchenko, Kirill A Dmitriev, Natalia V Vostokova, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Medicinal Chemistry|August 14, 2020
Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza VirusesAndrei A Ivashchenko, Oleg D Mitkin, Jeremy C Jones, et al.
Emerging Infectious Diseases|March 10, 2025
Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023-2024Philippe Noriel Q Pascua, Anton Chesnokov, Ha T Nguyen, et al.
Antiviral Research|July 26, 2023
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022Ha T Nguyen, Anton Chesnokov, Juan De La Cruz, et al.
Journal of Medicinal Chemistry|August 23, 2014
Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025)Alexandre V Ivachtchenko, Oleg D Mitkin, Pavel M Yamanushkin, et al.
Viruses|July 2, 2021
Effect of Aprotinin and Avifavir<sup>®</sup> Combination Therapy for Moderate COVID-19 PatientsAndrey A Ivashchenko, Valeria N Azarova, Alina N Egorova, et al.
The Journal of Antimicrobial Chemotherapy|December 28, 2020
Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavirAndrei A Ivashchenko, Oleg D Mitkin, Jeremy C Jones, et al.
Journal of Psychiatric Research|October 17, 2021
Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot studyAndrey A Ivashchenko, Margarita A Morozova, Natalia V Vostokova, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 10, 2020
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical TrialAndrey A Ivashchenko, Kirill A Dmitriev, Natalia V Vostokova, et al.
Pageof 7